Physicians' Academy for Cardiovascular Education

Understanding new PCSK9 outcome data: From the LDL-C hypothesis to LDL-c causality

Aug. 26, 2017 - ESC 2017, Barcelona, Spain - John Chapman, PhD, Paris, France - PACE-CME symposium

This lecture was part of a CME accredited symposium: PCSK9 inhibition & Cardiovascular Outcomes: Review of lipid targets and treatment strategies held at ESC 2017 in Barcelona

Video navigation menu

  • LDL-c in the pathophysiology of atherosclerosis 2:42
  • Once a fatty streak lesion is present, plaque inflammation develops and the plaque progresses 5:04
  • Cholesterol crystals characterize mature plaques 7:14
  • How did prevention trial interventions impact on the pathogenesis of atherosclerosis? 8:33
  • Potential mechanisms of how LDL-c lowering regresses and stabilizes plaques 11:56
  • Evidence accumulates: LDL is causal in ASCVD  13:30

Educational information

The educational objectives of the symposium were to:

Disclosures

John Chapman is Research Professor at the Pierre and Marie Curie University, and Director Emeritus of the National Institute for Health and Medical Research (INSERM) at the Pitié-Salpêtrière University Hospital in Paris, France

CME Accreditation

This programme was accredited by the European Board for Accreditation in Cardiology (EBAC) for 1 hour of external CME credit(s).

Funding

This symposum was supported by unrestricted educational grants provided by Amgen and Sanofi-Regeneron

Download abstract and key slides View and download slides